Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sanofi’s Diabetes Drug Hits Phase 3 Study Targets

By Ryan Bushey | June 14, 2016

Sanofi announced on Sunday that its combination diabetes therapy, LixiLan, achieved its primary endpoints in two pivotal phase 3 studies. LixiLan, which comprises basal insulin Lantus and the GLP-1 drug lixisenatide, is a single injection designed to treat type 2 diabetes.

Participants in both studies were type 2 diabetes patients who were unable to control their blood sugar levels with metformin or metformin in conjunction with another add-on drug, wrote FiercePharma. Metformin treatment regimens were continued during the process.

The first study, labeled LixiLan-O, focused on comparing the efficacy of the combination product against its core ingredients over a 30-week period with 1,170 patients. Results demonstrated that LixiLan substantially reduced A1C levels by 1.6 percent whereas Lantus lowered it by 1.3, and lixisenatide only hit 0.9 percent.

The second trial, labeled LixiLan-L, yielded similar results with a smaller margin. The combination drug delivered an A1C reduction of 1.1 percent while the Lantus arm only lowered A1C by 0.6 percent.

Both trials reported similar adverse events like nausea and vomiting, added FiercePharma, although hypoglycemia rates varied.

Sanofi unveiled these results at the annual American Diabetes Association meeting in New Orleanswhere the company noted the data will be included in U.S. and European regulatory submissions.

The French drug maker expects to have LixiLan approved in the U.S. this August followed by a first-quarter approval in Europe next year, according to Reuters.

LixiLan sales are projected to reach an approximate $1 billion in 2020.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE